Pilot Study of Homebound Stem Cell Transplantation for Patients with Multiple Myeloma


Full Title

Pilot Trial of Homebound Stem Cell Transplantation


Autologous stem cell transplantation (ASCT) is a treatment in which some of a patient’s stem cells are removed before high-dose chemotherapy, then returned to the patient to help re-establish the patient’s immune system after chemotherapy. Care for a patient after ASCT usually takes place in a hospital. In this study, researchers want to see if it is feasible to care for a patient at home after ASCT for multiple myeloma. Studies at other institutions suggest that providing care at home after ASCT is safe, increases patient satisfaction, and can lower the risk of infection.

Patients in this study will have their stem cells re-infused in an outpatient setting in the hospital and then continue their care at home.

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have multiple myeloma and plan to have ASCT.
  • Patients must have adequate caregiver support and a wireless Internet connection at the home where they will be recovering after ASCT.
  • This study is for people ages 18 to 80.

For more information about this study and to inquire about eligibility, please contact Dr. Heather Landau at 212-639-8808.




Pilot (small research study)


ClinicalTrials.gov ID